Apollon Wealth Management LLC Buys 962 Shares of Moderna, Inc. (NASDAQ:MRNA)

Apollon Wealth Management LLC lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 23.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,064 shares of the company’s stock after acquiring an additional 962 shares during the period. Apollon Wealth Management LLC’s holdings in Moderna were worth $338,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the second quarter worth $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter worth $33,000. Bank & Trust Co purchased a new stake in shares of Moderna in the second quarter worth $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna in the second quarter worth $48,000. Finally, Plato Investment Management Ltd raised its position in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 7.3 %

Shares of NASDAQ:MRNA opened at $36.85 on Monday. The stock’s 50-day moving average price is $58.56 and its 200-day moving average price is $96.78. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The stock has a market capitalization of $14.18 billion, a P/E ratio of -6.33 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned ($1.39) earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -9.43 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. TD Cowen lowered their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Bank of America lowered their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Wolfe Research started coverage on Moderna in a research report on Friday. They set an “underperform” rating and a $40.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $90.22.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,930 shares of company stock valued at $217,170 over the last ninety days. 15.70% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.